Why epigenetics?
Connecting gene regulation, disease biology and biomarker discovery
MiND Biosciences is developing a multi-omic biomarker discovery platform that combines epigenetic, epitranscriptomic and transcriptomic analysis to identify molecular signatures associated with neurodegenerative disease. By connecting biological discovery with clinical translation, our research aims to support earlier diagnosis, improved disease monitoring and future therapeutic development.
Our platform
Disease biology
Understanding molecular mechanisms associated with neurodegeneration.
Epigenetic discovery
Identifying disease-associated changes in DNA and RNA.
Biomarker signature development
Defining multi-marker patterns that may reflect disease biology.
Blood-based assay pathway
Progressing toward minimally invasive molecular testing.
Clinical utility
Exploring applications in diagnosis, prognosis, monitoring and clinical trial support.
What is an epigenetic biomarker?
Epigenetics concerns changes in how genes are regulated without changing the underlying DNA sequence. MiND also studies RNA modifications and gene activity to build a broader picture of disease-related molecular changes.
A biomarker is a measurable biological signal. Our research asks whether patterns within these molecular layers could provide useful information about MND/ALS.
Why a platform matters
The platform provides a framework for identifying and evaluating biomarker candidates. MND/ALS is the initial focus. Evidence from this programme may inform future research in other neurodegenerative diseases, with each new application requiring its own validation.
Explore a scientific collaboration
We welcome discussions about research, validation and diagnostic development. More detailed technical information may be shared through an appropriate confidential review process.
Partner with us
MiND Biosciences is committed to advancing biomarker discovery through collaboration. We welcome opportunities to work with researchers, clinicians, industry partners and investors who share our vision for earlier, more precise diagnosis.